Oren Gilad

Atrin Pharmaceuticals LLC, based in Doylestown, PA, is an emerging growth biopharmaceutical company focused on discovering and developing proprietary medications for the treatment of cancers that currently do not have effective therapies using technology developed and licensed in association with the University of Pennsylvania in a royalty-free transaction. This technology represents a new approach for treating solid tumors that currently have limited or ineffective therapies, including breast, pancreatic, lung, ovarian and colon cancers. Atrin is developing a portfolio of small molecule drug candidates targeting several oncological indications via multiple mechanisms of action. Our lead product, a novel inhibitor of ATR, is a water soluble and orally bioavailable small molecule. It has produced excellent preclinical results in ovarian, pancreatic, prostate and colon cancer indications, and we are now exploring brain cancer. We have verified that our lead compound is synthetically lethal with oncogenic stress, alternative lengthening of telomeres (ALT) and defects in homologous recombination (HR) genes, such as BRCA1 and BRCA2, and are efficacious in vivo, causing tumor suppression as a monotherapy, regression in combination therapy, and is well tolerated in mice at therapeutic doses. Atrin is also developing a portfolio of additional oncology small molecule candidates encompassing different mechanisms of action based on the focused inhibition of essential pathways in cancer cells. Atrin has furthermore developed an innovative, high-throughput, human cell-based screening platform, called Atrize, with applications to drug discovery, development, and to personalized medicine.